DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Eskalith Cr is a drug marketed by Jds Pharms and is included in one NDA.
The generic ingredient in ESKALITH CR is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
A generic version of ESKALITH CR was approved as lithium carbonate by HIKMA on January 29th, 1982.
Recent Clinical Trials for ESKALITH CR
Identify potential brand extensions & 505(b)(2) entrants
|Patient-Centered Outcomes Research Institute||Phase 4|
|Washington University School of Medicine||Phase 4|
|University Hospitals Cleveland Medical Center||Phase 4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Jds Pharms||ESKALITH CR||lithium carbonate||TABLET, EXTENDED RELEASE;ORAL||018152-001||Mar 29, 1982||DISCN||No||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|